Use of Local Infiltration Analgesia Following Total Hip Arthroplasty

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this study is to evaluate if multiple postoperative administrations with a solution of ropivacaine, ketorolac and epinephrine into the operating field through a catheter would affect morphine consumption. Secondary end-points are pain intensity, side effects and length of stay.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Local Infiltration Analgesia in Total Hip Arthroplasty

NCT00968955

Post-operative Pain

COMPLETED PHASE4

Intraarticular Analgesia After Total Hip Arthroplasty, a Randomised Study

NCT00289419

Arthroplasty, Replacement, Hip

COMPLETED PHASE4

Pain Management Following Total Hip Arthroplasty

NCT02568995

Postoperative Pain Intensity Rescue Pain Requirements

COMPLETED PHASE3

Postoperative Analgesia After Total Knee Arthroplasty

NCT00421967

Arthroplasty, Replacement, Knee

TERMINATED PHASE4

Implementation of a Pain Management Protocol for Total Knee Arthroplasty

NCT02474654

Knee Replacement, Total

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RK-group

Group Type EXPERIMENTAL

ropivacaine and ketorolac

Intervention Type DRUG

The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively

K-group

Group Type ACTIVE_COMPARATOR

Ketorolac

Intervention Type DRUG

The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ropivacaine and ketorolac

The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively

Intervention Type DRUG

Ketorolac

The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled for total hip arthroplasty
* Patients \> 18 years of age
* Signed written informed consent
* Spinal anaesthesia

Exclusion Criteria

* Allergy towards study drugs
* Rheumatoid arthritis
* Body Mass Index \> 35 (severe obesity)
* Pregnancy or nursing women
* Regular opioid use
* Patients who can not read or understand danish

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No